

FC49 Neurosciences, psychopharmacology and biological psychiatry**THERAPEUTIC DRUG MONITORING (TDM) AND POPULATION PHARMACOKINETICS (PPK)**

E. Bengtsson, P. Höglund, A. Liden, C. Nordin, J. Walinder. Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden.

Thymoleptic SSRIs F=fluvoxamine (introduced in Sweden in June 1990), P=paroxetine (June 1991) and C=citalopram (+ desmethylcitalopram; Oct. 1992) were subjected to postmarketing surveillance by introducing serum RP-HPLC (UV-detect.) analytical methods determining the F (from Oct. 1992), P (Nov. 1992), and C (April 1993) for routine use in southern Sweden (pop. 3 mill). Specifically designed TDM-request forms were used to acquire adequate clinical data. Stratification of the data made us perform traditional statistics as well as PPK modelling on this large and naturalistic clinical phase-IV cohort. By June 1994 the collection of such data amounted to 363 (F), 775 (P) and 778 (C) TDM-analyses. Eligible data were subjected to NONMEMR PPK-calculations and as an example the paroxetine estimates from two time points (Oct. 1993; 129 TDM-analyses/115 patients and June 1994; 333 TDM-analyses/268 patients) displayed: $cl_{1/2}$ 11/2 to be dependent on sex and co-medication; 11/2 = males 28 h vs. females 36 h. Vd was dependent on sex; males 281 L vs. females 406 L. Oral clearance (Cl_o) was dependent on sex, age and co-medication:

Patient age (years)	20	40	60	80
Cl _o at monotherapy (L per h): Males	38	32	26	19
Females	29	24	20	15

PPK calculations for F and C will be discussed in detail in the presentation. Developing clinical trials TDM-routines for the SSRIs served several important purposes. Firstly, the physicians were assisted in optimizing their dosing strategies for each individual patient in the complex true clinical setting where these drugs are used. Secondly, as exemplified, the PPK modelling for P unravelled clearcut aberrations in kinetic features in agreement with the scarce reports found in the literature. We submit that this clinically relevant postmarketing surveillance strategy has the potential to greatly improve drug safety in psychiatric practice.

FC51 Neurosciences, psychopharmacology and biological psychiatry**CORPUS CALLOSUM AREA (CCA) IN SCHIZOPHRENIC PATIENTS**

G. Bersani¹, A. Iannuti¹, C. Silvestrini¹, P. Cipriano¹, C. Zucca¹, F. Pontieri², G.F. Gualdi³, C. DiBiasi³, G. Trasimeni³, P. Pancheri¹

¹ III Psychiatric Clinic, ² I Neurological Clinic, ³ I Medical Clinic, MRI-TC Unit, "La Sapienza" University, Rome

Since some observations in schizophrenic subjects suggest a sexual dimorphism in CCA, where "schizophrenic women account for most of the variance" (1), aim of the study was to verify whether there are some differences in MRI CCA measurements between male individuals discordant for schizophrenia. Moreover, to examine the hypothesis suggesting an association between hallucinations and a disruption of interhemispheric communication in schizophrenia (2), we investigated possible correlates between CCA and SAPS-hallucination scores.

We used MRI techniques to derive CCA measurements in 18 men (mean age = 28.2 ± 4.5 SD) meeting DSM-III-R diagnosis of schizophrenia and in 18 age- and sex-matched healthy controls. We measured by a 4-mm-slice midsagittal section brain area (BA), CCA and CCA to BA ratio (CCBR).

Schizophrenic patients and controls showed by the ANOVA analysis a homogeneous BA, CCA and CCBR value.

In the schizophrenics CCBR correlated at a positive statistically significant level ($p < 0.05$) with SAPS-total-hallucination and SAPS-auditory-hallucination scores.

The results confirm previous studies (3), indicating the existence of sexual dimorphism, in some brain areas, in schizophrenia. In addition, our finding of an increase in the severity of hallucinations related to the size of CCA support the intriguing hypothesis linking an integration of the hemispheres potentially independent thoughts with the hallucinatory symptoms in schizophrenia.

(1) Nasrallah H.A., Andreasen N.C., Coffman J.A., Olsen S.C., Dunn V.D., Ehrhardt J., Chapman S. A controlled Magnetic Resonance Imaging study of corpus callosum thickness in schizophrenia. *Biological Psychiatry* 1986;21:274-282.

(2) Doty R., Schizophrenia: a disease of interhemispheric processes at forebrain and brainstem levels? *Behavioural Brain Research* 1989;34:1-33.

(3) Cowell P.E., Kostanovsky D.J., Gur R.C., Turetsky B.I., Gur R.E. Sex differences in Neuroanatomical and Clinical Correlations in Schizophrenia. *American Journal of Psychiatry* 1996;153:799-805.

This study was supported by CNR grant (MRI-Project 1995-1997)

FC50 Neurosciences, psychopharmacology and biological psychiatry**SUPERIOR TEMPORAL GYRUS VOLUME (STGV) IN SCHIZOPHRENICS**

G. Bersani¹, A. Iannuti¹, C. Silvestrini¹, P. Cipriano¹, C. Zucca¹, F. Pontieri², G.F. Gualdi³, C. DiBiasi³, G. Trasimeni³, P. Pancheri¹

¹ III Psychiatric Clinic, ² I Neurological Clinic, ³ I Medical Clinic, MRI-TC Unit, "La Sapienza" University, Rome

Since precedent studies showed an association between auditory hallucinations in schizophrenia and some pathologic areas in left temporal lobe (1), we measured STGV to examine this hypothesis.

We derived by MRI measurements of the anterior STGV in 15 right-handed men (mean age 27.5 ± 7.5 SD) with a DSM-III-R diagnosis of Schizophrenia (undifferentiated, N=6, paranoid, N=5, disorganized, N=2, catatonic, N=2) and in 15 age- and sex-matched healthy controls.

Anterior STGV was measured in three consecutive coronal 4-mm-slices (two where the amygdala was visible, plus the next anterior slice).

STGV in the two hemispheres was almost the same size in controls, while in the schizophrenics we found a 20% reduction in the left side. As compared with controls, patients showed significant reductions in the left anterior STGV (in the right side by 9% and in the left side by 14%) and a positive correlation between percent difference in left STGV and SAPS-auditory-hallucinations score ($p < 0.05$).

The results suggest that a reduction of the left STGV in schizophrenic subjects appears strongly correlated with severity of auditory hallucinations.

Our finding agrees with previous MRI, SPECT (2) and PET (3) studies that report a volumetric and functional reduction of the left STG in schizophrenic patients with severe auditory hallucinations.

(1) Barta P.E., Pearlson G.D., et al. Auditory hallucinations and smaller superior temporal gyrus volume in schizophrenia. *American Journal of Psychiatry* 1990;147:1457-1462.

(2) McGuire P.K., Shah G.M., Murray R.M. Increased blood flow in Broca's area during auditory hallucinations in schizophrenia. *Lancet* 1993;342:703-706.

(3) Clegghorn J.M., Franco S., et al. Toward a brain map of auditory hallucinations. *American Journal of Psychiatry* 1992;149:1062-1069.

This study was supported by CNR grant (MRI-Project years 1995-1997)

FC52 Neurosciences, psychopharmacology and biological psychiatry**A FOLLOW UP STUDY OF THE TREATMENT OF FRAGILE X SYNDROME**

H. Bleiweiss, A. Goldemberg, M. Staszauer. Centro de Psiquiatria Genética, Av. Santa Fé 931, 2nd Floor, Buenos Aires, Argentina.

A follow up study of the treatment of Fragile X patients: To show positive results in patients with fragile X syndrome, after several years of control - all patients to be included in our study underwent different treatments without positive results. In this way the patient controlled himself. Everyone had done a chromosomal study, a psychiatric interview and a topographic brain tomography when needed. We made an agreement with the patients' family saying that the patient will receive a trial treatment for 4 months with a monthly evaluation. Expectatives were that clinical changes must be clear enough so that everybody could see them. Lithium, haloperidol, folic acid, vit. E, nicotinamide and GABA were given - 90% improved. In general there was an improvement in learning capacities in 67%, attention and hiperkinesia in 61%, writing in 62%, social behavior in 33%. Side effects were seen in 1.2% as slightly excited or nervous. Side effects disappear when medication was withheld for 72 Hs. and lower doses were used. Quality of life for both patients and family improved.